Conjugated peptides include a first peptide component which is an antigen
associated with autoimmune disease, allergy, asthma or transplantation
rejection and binds to an antigen-specific receptor on a T cell, and a
second peptide component which corresponds to an "antigen presenting
molecule" namely, a peptide binding to a T cell surface receptor, which
would normally promote T cell activation when the first peptide is bound
to its antigen-specific T cell receptor. However, in this invention, the
second peptide component has an amino acid sequence which is a
modification of an antigen presenting T cell binding peptide, such
modification blocking or inhibiting the engagement of receptor sites on
the T cell surface (other than the antigen-specific T cell receptor). As
a result of the inhibition/blocking, T cell activation is prevented, and
is directed through antigen-specific T cell receptor occupation, without
T cell activation, leading to antigen-specific T cell anergy and cell
death. Administration of the conjugated peptide to an animal, e.g.,
human, will provide that animal with protection against the disease
associated with the first peptide component, resulting from the
elimination of the T cells bearing the antigen-specific receptors for
that antigenic peptide. The conjugated peptides of this invention provide
antigen-specific protection without impairing the immune response to
other antigens, including pathogens.